Eberlein-König B, Jung C, Rakoski J, Ring J
Klinik und Poliklinik für Dermatologie und Allergologie am Biederstein, Technische Universität München, Klinische Kooperationsgruppe Umweltdermatologie und Allergologie GSF/TUM, Neuherberg-München, Munich, Germany.
Clin Exp Allergy. 1999 Dec;29(12):1641-7. doi: 10.1046/j.1365-2222.1999.00671.x.
Reduction in the size of the allergen-induced late-phase reaction (LPR) is seen as a consequence of successful allergen specific immunotherapy.
It was the aim of this study to characterize the cellular infiltrate at the sites of cutaneous LPR that may occur following injection of a depot pollen allergoid (Allergovit(R)) during immunotherapy and thereby determine the immunological nature of the response.
Punch biopsies were taken 24 h after subcutaneous injection of a depot pollen allergoid from eight patients that showed LPR and a further five patients that did not. Additional biopsies taken 24 h after injection of allergoid-free depot in the same patients served as controls. Immunoenzymatic labelling of the cryostat sections with different antibodies was performed with the APAAP technique. Results were expressed as cells/field (400 x magnification).
Similar dermal cellular infiltrations were seen following depot allergoid injections in patients both with and without LPR. Patients with LPR showed statistically significant increases in total cells, CD4+ cells, CD11c+ cells, CD45RO+ cells, CD45RB+ cells and activated eosinophils at the reactions sites as compared with control sites. In patients without LPR CD11c+ cells, HLA-DR+ cells and CD45RA+ T cells increased significantly. CD8+, CD1a+, NP57+, CD23+ and CD25+ cells did not differ significantly in either group.
These results indicate that activation of T cells, monocytes/macrophages and eosinophils at the sites of LPR following injection of depot allergoid are comparable with those following injection of allergen. Even in the absence of a cutaneous LPR, subsets of T cells and monocytes/macrophages increased. These cell activations may reflect events associated with the mechanisms of allergoid-based specific immunotherapy, and suggest that at least part of the late-phase reaction may be independent of IgE.
变应原诱导的迟发相反应(LPR)大小的减小被视为变应原特异性免疫治疗成功的结果。
本研究旨在对免疫治疗期间注射长效花粉类变应原(Allergovit®)后可能出现的皮肤LPR部位的细胞浸润进行特征描述,从而确定反应的免疫性质。
对8例出现LPR的患者以及另外5例未出现LPR的患者,在皮下注射长效花粉类变应原24小时后进行打孔活检。在同一患者中注射无变应原长效制剂24小时后进行的额外活检用作对照。采用抗过氧化物酶-抗碱性磷酸酶(APAAP)技术,用不同抗体对冰冻切片进行免疫酶标记。结果以细胞/视野(400倍放大)表示。
无论有无LPR,患者在注射长效类变应原后均出现类似的真皮细胞浸润。与对照部位相比,出现LPR的患者在反应部位的总细胞、CD4 +细胞、CD11c +细胞、CD45RO +细胞、CD45RB +细胞和活化嗜酸性粒细胞有统计学意义的增加。在无LPR的患者中,CD11c +细胞、HLA-DR +细胞和CD45RA + T细胞显著增加。两组中CD8 +、CD1a +、NP57 +、CD23 +和CD25 +细胞无显著差异。
这些结果表明,注射长效类变应原后LPR部位的T细胞、单核细胞/巨噬细胞和嗜酸性粒细胞的活化与注射变应原后的情况相当。即使没有皮肤LPR,T细胞和单核细胞/巨噬细胞亚群也会增加。这些细胞活化可能反映了与类变应原特异性免疫治疗机制相关的事件,并表明迟发相反应的至少一部分可能与IgE无关。